Foghorn Therapeutics Files 8-K Reporting Q2 2026 Financial Results

What Happened

• On August 6, 2026, Foghorn Therapeutics, Inc. announced and furnished a press release reporting certain financial results for the quarter ended June 30, 2026. The press release is included as Exhibit 99.1 to the Form 8-K.
• The company also furnished an investor presentation dated August 2026 that it intends to use in meetings with or presentations to investors; that presentation is included as Exhibit 99.2. The disclosure was made under Regulation FD.

Key Details

• Press release announcing quarterly financial results furnished on August 6, 2026 (Exhibit 99.1).
• Quarter covered: quarter ended June 30, 2026 (Q2 2026).
• Investor presentation dated August 2026 furnished for use in investor meetings (Exhibit 99.2).
• Disclosure provided under Regulation FD to ensure broad, simultaneous access to the materials.

Why It Matters

• This 8-K provides the company’s latest quarterly results and investor materials; investors should review the furnished press release and presentation to assess Foghorn’s recent earnings, revenue trends, cash position, and operational progress.
• Because the materials were furnished under Regulation FD, the information is intended to be publicly available to all investors at the same time, which can affect trading sentiment and valuation as market participants digest the quarterly results.